Alumis Announces Pricing of Initial Public Offering
In This Article:
SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (“Alumis” or the “Company”) (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the pricing of its initial public offering of 13,125,000 shares of common stock at an initial public offering price of $16.00 per share. All shares of common stock are being offered by Alumis. In addition, Alumis has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,968,750 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on Nasdaq on June 28, 2024 under the symbol “ALMS.” The offering is expected to close on July 1, 2024, subject to the satisfaction or waiver of customary closing conditions.
Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities are acting as joint book-running managers for the offering.
In addition to the shares being sold in the initial public offering, Alumis also announced today that it has agreed to sell an additional 2,500,000 shares of its common stock in a concurrent private placement at $16.00 per share to one of its existing investors, AyurMaya Capital Management Fund, LP. The sale of these shares of common stock will not be registered under the Securities Act of 1933, as amended, and as such, the shares may not be offered or sold absent registration or an applicable exemption from registration. The concurrent private placement shares are subject to existing resale registration rights and will be subject to a 180-day lock-up agreement. The concurrent private placement is expected to close after the closing of the initial public offering on or before July 22, 2024. The closing of the concurrent private placement is conditioned on the closing of the initial public offering.
The gross proceeds to Alumis from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions and offering and private placement expenses payable by Alumis, are expected to be $250.0 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock.
A registration statement relating to the securities being offered and sold in this offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on June 27, 2024. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, a copy of the final prospectus relating to this offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].